Doses were inconsistent, side effects showed up more often than expected, and in some cases, the risks were serious enough to outweigh any potential benefits
After 12 weeks, increased conversion of testosterone to the more potent androgen dihydrotestosterone, as well as improved sperm count and motility, were seen

Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
Results you can feelsafely
This suggests that microneedling's benefits are cumulative
Think of the motion as warming a cold drink in your hands, gentle and even